These results supported the notion that, in bladder cancer, NF-κB could sustain its activation through a feedback loop in which NF-κB induced miR-130b expression, which consequently inhibited the expression of the endogenous NF-κB blocker, CYLD. Here, NFKB1 is linked to urinary bladder carcinoma.